Work

Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

Year: 2012

Type: article

Source: Bioorganic & Medicinal Chemistry Letters

DOI: 10.1016/j.bmcl.2012.06.018

Authors: Bruce J. Melancon, Thomas J. Utley, Christian Sevel, Margrith E. Mattmann, Yiu-Yin Cheung, Thomas M. Bridges, Ryan D. Morrison, Douglas J. Sheffler, Colleen M. Niswender, J. Scott Daniels, P. Jeffrey Conn, Craig W. Lindsley, Michael R. Wood

Institutions: Vanderbilt University, Vanderbilt University Medical Center

Language: English

Topic: Receptor Mechanisms and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke

Awards: G2471675597, G2478413624, The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, G574656479, G663594137, Udall Parkinson's Disease Center at Emory University: Circuitry to Therapy, Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia, Postdoctoral Training in CNS Drug Discovery Research

OpenAlex ID: W2104566960

FWCI: 0.348

Cites: 21

Cited by: 16

Related to: 10